Search
FABRAZYME 35 MG, Poudre pour solution à diluer pour perfusion
Details
| --- | Description |
|---|---|
| Pack | Boite de 1 flacon de 20 ml |
| Strength (Dosage) | 35 MG |
| Laboratory | SANOFI AVENTIS MAROC |
| Ingredients | Agalsidase bêta |
| Therapeutic class | Agalsidase bêta (produite par technologie de l’ADN recombinant à partir de cultures de cellules de mammifères extraites d’ovaires de hamster chinois (CHO)) (35 mg) |
| ATC code | A16AB04 |
| PPH | $3,479.80 |
| PPV | $3,548.60 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Traitement enzymatique substitutif chez les patients atteints de la maladie de Fabry (déficit en α-galactosidase A). Les données concernant l’efficacité et la sécurité ont été évaluées pour une durée de traitement allant jusqu’à 18 mois. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem